GERMANTOWN, Md., Aug. 1 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of J. Michael Hamilton, M.D., to the newly created position of Chief Medical Officer effective August 1, 2006. He will report to Kenneth C. Carter, Ph.D., President and CEO of Avalon Pharmaceuticals.
“The addition of Dr. Hamilton is perfectly timed because our first lead drug candidate, AVN944, is currently in a complex clinical trial that includes patients with several kinds of hematological cancers including acute leukemia, myeloma and lymphoma,” said Dr. Carter. “Michael’s wealth of experience in the management, design and execution of drug trials will help with both the AVN944 clinical program and our plans to move our other drug candidates into the clinic.”
As Chief Medical Officer, Dr. Hamilton will develop clinical strategies and priorities, and also oversee implementation of Phase I-III clinical trials. He will also be responsible for regulatory affairs and interaction with the FDA. As a key member of senior management, Dr. Hamilton will also participate in defining strategic direction and program development for the Company.
Dr. Hamilton brings to Avalon 20 years of expertise in the field of oncology. Most recently, from 2000-2005, he served as Group Director of Oncology, MDC and led a portfolio of U.S. clinical trials for oncology for GlaxoSmithKline. He coordinated the oncology group’s clinical activities from drug discovery and development through clinical trials and the regulatory process. There he oversaw the development of a number of drug candidates including small molecules, antibodies and tumor vaccines. Dr. Hamilton was also actively involved in the evaluation of in-licensing drug candidates for development.
Dr. Hamilton comments, “I am excited about the opportunity to join Avalon, a young, vibrant company where my contributions will have a direct and immediate impact. Avalon’s approach to drug discovery, which uses a systems biology approach that measures alterations in key disease pathways, is very unique and I believe my clinical experience will add important value in the Company’s drug discovery effort.”
Prior to his work at GlaxoSmithKline, Dr. Hamilton held the positions of Section Chief of Clinical Investigations and Program Director for the National Cancer Institute (NCI) where he was involved in the development and execution of numerous clinical trials and oncology. As Director of NCI Medical Oncology Fellowship Training Program, he supervised clinical training of 30 fellows. As Clinical Director, he was responsible for supervision of NCI medical oncology research, inpatient and clinical nursing staff and for operations of the National Naval Medical Center/NCI inpatient, oncology ward and outpatient Hematology-Oncology clinic. Earlier in his career at NCI, Dr. Hamilton also worked as a Senior Investigator at the Cancer Therapy Evaluation Program where he was the NCI liaison to NCI Multi-institutional Cooperative Groups. There he designed and reviewed clinical trials in various disease areas and assisted in the review of clinical protocols. He also convened panels for expert planning of disease strategies and coordinated the planning of large intergroup clinical trials.
Dr. Hamilton received his Bachelor’s degree from the University of Connecticut and his M.D. from the George Washington University. He completed his residency at the Washington Hospital Center in Washington, D.C. He is a licensed M.D. in Maryland and board certified in Internal Medicine and Medical Oncology. Dr. Hamilton is also a member of the American Society of Clinical Oncology, The American Society for Hematology, The American Association for Cancer Research and the European Hematology Association.
About Avalon Pharmaceuticals
Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics through the use of a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis which it calls AvalonRx(R). This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response. Avalon’s focus is oncology but the company has discovery programs in other therapeutic areas with partners. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Maryland.
Contacts: Avalon Pharmaceuticals, Inc. Gary Lessing Executive Vice President & CFO Tel: (301) 556-9900 Fax: (301) 556-9910 Email: info@avalonrx.com Noonan Russo Wendy Lau (Media) Tel: (212) 845-4272 Matthew Haines (Investors) Tel: (212) 845-4235
Avalon Pharmaceuticals, Inc.
CONTACT: Gary Lessing, Executive Vice President & CFO of AvalonPharmaceuticals, Inc., +1-301-556-9900, Fax: +1-301-556-9910,info@avalonrx.com; or Media: Wendy Lau, +1-212-845-4272, or Investors:Matthew Haines, +1-212-845-4235, both of Noonan Russo, both for AvalonPharmaceuticals, Inc.
